Defend International is pleased to inform its members and supporters that the 12th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB) will be held from 20 to 24 April 2018 in Melbourne, Victoria, Australia.
The 12th Congress of the WFNMB will bring together nuclear medicine physicians, radiologists, medical imaging trainees, physicists, scientists, technologists, nurses, and the broader medical and scientific community to discuss . The program includes plenary sessions, continuing educations sessions, and large poster presentation sessions. The Victorian Government is offering a number of travel assistance grants for participants from developing countries.
Professor Andrew Scott, the Director of the Department of Molecular Imaging and Therapy at Austin Health in Australia, said that “The Congress seeks to promote further global translation of molecular medicine incorporating the translation of basic laboratory research to clinical practice, establishment of clinical and technical standards, and the translation of molecular medical technology to developing countries for the benefit of patients worldwide.”
“You will enjoy five days of education and networking in one of the most technologically advanced and environmentally friendly convention centres in the world – the Melbourne Exhibition and Convention Centre – which is situated in the heart of the city centre surrounded by hotels, dining and entertainment options, attendees can enjoy the safe and friendly city of Melbourne. Melbourne has been consistently nominated as the most liveable city in the world for five years in a row since 2011, and is a vibrant, cosmopolitan capital city of Victoria, Australia, with a distinct atmosphere due to its multicultural population, extensive food and wine culture, and is the arts and cultural centre of Australia with a unique architectural heritage. By attending this Congress, you will make fruitful connections, gain insight into the latest research, clinical and technical standards, imaging and treatment strategies, and bring the latest in molecular imaging and therapeutic care back to your patients.”